We previously reported the identification of ATase1/ATase2‐specific inhibitors (Ding et al., 2012); we also reported the successful use of one of these compounds (6‐chloro‐5H‐benzo[a]phenoxazin‐5‐one; referred to as compound 9) in a mouse model of Alzheimer's disease (Peng et al., 2016). Here, NAT8 is linked to early-onset autosomal dominant Alzheimer disease.